Analyst Price Target is $40.00
▲ +496.57% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Precipio in the last 3 months. The average price target is $40.00, with a high forecast of $40.00 and a low forecast of $40.00. The average price target represents a 496.57% upside from the last price of $6.71.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Precipio. This N/A consensus rating has held steady for over two years.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.
Read More